Transcatheter Aortic Heart Valves: Histological Analysis Providing Insight to Leaflet Thickening and Structural Valve Degeneration.


Journal

JACC. Cardiovascular imaging
ISSN: 1876-7591
Titre abrégé: JACC Cardiovasc Imaging
Pays: United States
ID NLM: 101467978

Informations de publication

Date de publication:
01 2019
Historique:
received: 13 02 2018
revised: 09 05 2018
accepted: 22 06 2018
pubmed: 19 11 2018
medline: 14 1 2020
entrez: 19 11 2018
Statut: ppublish

Résumé

This study investigated processes causing leaflet thickening and structural valve degeneration (SVD). Although transcatheter aortic valve replacement (TAVR) has changed the treatment of aortic stenosis, concerns remain regarding SVD, potentially related to valve thrombosis and thickening, based on studies using computed tomography (CT). Detailed histological analyses are provided to help attain insights into these processes. Explanted transcatheter heart valves (THVs) were evaluated for thrombosis, fibrosis, and calcification for quantification of leaflet thickness. Immunohistochemical and microscopy approaches were used to investigate SVD-associated mechanisms. THVs (n = 23) were obtained from 22 patients (median 81 years of age; 50% male) from 0 to 2,583 days post TAVR. Maximal leaflet thickness increased relative to implant duration (ρ = 0.427; p = 0.027). THVs explanted after >2 years were thicker than those explanted after <2 years (p = 0.007). All THVs had adherent thrombus on both aortic and ventricular sides, which beyond 60 days was seen in combination with fibrosis and beyond 4 years had calcification. Early thrombus formation (<60 days) occurred despite rapid endothelialization with an abnormal hyperplastic phenotype. Fibrosis was observed in 6 patients on both the aortic and the ventricular THV surfaces, remodeled over time, and was associated with matrix metalloproteinase-1 expression. Five THVs showed overt calcification associated with adherent thrombus and fibrosis. There is a time-dependent degeneration of THVs consisting of thrombus formation, endothelial hyperplasia, fibrosis, tissue remodeling, proteinase expression, and calcification. Future investigation is needed to further understand these mechanisms contributing to leaflet thickening and SVD.

Sections du résumé

OBJECTIVES
This study investigated processes causing leaflet thickening and structural valve degeneration (SVD).
BACKGROUND
Although transcatheter aortic valve replacement (TAVR) has changed the treatment of aortic stenosis, concerns remain regarding SVD, potentially related to valve thrombosis and thickening, based on studies using computed tomography (CT). Detailed histological analyses are provided to help attain insights into these processes.
METHODS
Explanted transcatheter heart valves (THVs) were evaluated for thrombosis, fibrosis, and calcification for quantification of leaflet thickness. Immunohistochemical and microscopy approaches were used to investigate SVD-associated mechanisms.
RESULTS
THVs (n = 23) were obtained from 22 patients (median 81 years of age; 50% male) from 0 to 2,583 days post TAVR. Maximal leaflet thickness increased relative to implant duration (ρ = 0.427; p = 0.027). THVs explanted after >2 years were thicker than those explanted after <2 years (p = 0.007). All THVs had adherent thrombus on both aortic and ventricular sides, which beyond 60 days was seen in combination with fibrosis and beyond 4 years had calcification. Early thrombus formation (<60 days) occurred despite rapid endothelialization with an abnormal hyperplastic phenotype. Fibrosis was observed in 6 patients on both the aortic and the ventricular THV surfaces, remodeled over time, and was associated with matrix metalloproteinase-1 expression. Five THVs showed overt calcification associated with adherent thrombus and fibrosis.
CONCLUSIONS
There is a time-dependent degeneration of THVs consisting of thrombus formation, endothelial hyperplasia, fibrosis, tissue remodeling, proteinase expression, and calcification. Future investigation is needed to further understand these mechanisms contributing to leaflet thickening and SVD.

Identifiants

pubmed: 30448122
pii: S1936-878X(18)30915-X
doi: 10.1016/j.jcmg.2018.06.028
pii:
doi:

Substances chimiques

MMP1 protein, human EC 3.4.24.7
Matrix Metalloproteinase 1 EC 3.4.24.7

Types de publication

Comparative Study Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

135-145

Subventions

Organisme : British Heart Foundation
ID : FS/13/77/30488
Pays : United Kingdom
Organisme : British Heart Foundation
ID : FS/14/78/31020
Pays : United Kingdom
Organisme : British Heart Foundation
ID : RG/16/10/32375
Pays : United Kingdom
Organisme : Wellcome Trust
ID : WT103782AIA
Pays : United Kingdom

Commentaires et corrections

Type : CommentIn
Type : CommentIn
Type : CommentIn

Informations de copyright

Copyright © 2019 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Auteurs

Stephanie L Sellers (SL)

Department of Radiology, St. Paul's Hospital and University of British Columbia, Vancouver, British Columbia, Canada; Centre for Heart Lung Innovation, St. Paul's Hospital and University of British Columbia, Vancouver, British Columbia, Canada.

Christopher T Turner (CT)

Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, British Columbia, Canada.

Janarthanan Sathananthan (J)

Centre for Heart Valve Innovation, St. Paul's Hospital, Vancouver, British Columbia, Canada.

Timothy R G Cartlidge (TRG)

British Heart Foundation Centre for Cardiovascular Science, University of Edinburgh, Edinburgh, Scotland, United Kingdom.

Frances Sin (F)

Department of Radiology, St. Paul's Hospital and University of British Columbia, Vancouver, British Columbia, Canada; Centre for Heart Lung Innovation, St. Paul's Hospital and University of British Columbia, Vancouver, British Columbia, Canada.

Rihab Bouchareb (R)

Pulmonary and Cardiology Research University Institute, Laval University, Quebec City, Quebec, Canada.

John Mooney (J)

Department of Radiology, St. Paul's Hospital and University of British Columbia, Vancouver, British Columbia, Canada.

Bjarne L Nørgaard (BL)

Department of Cardiology, Aarhus University Hospital Skejby, Aarhus, Denmark.

Jeroen J Bax (JJ)

Department of Cardiology, Leiden University Medical Centre, Leiden, South Holland, the Netherlands.

Pascal N Bernatchez (PN)

Centre for Heart Lung Innovation, St. Paul's Hospital and University of British Columbia, Vancouver, British Columbia, Canada.

Marc R Dweck (MR)

British Heart Foundation Centre for Cardiovascular Science, University of Edinburgh, Edinburgh, Scotland, United Kingdom.

David J Granville (DJ)

Centre for Heart Lung Innovation, St. Paul's Hospital and University of British Columbia, Vancouver, British Columbia, Canada; Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, British Columbia, Canada.

David E Newby (DE)

British Heart Foundation Centre for Cardiovascular Science, University of Edinburgh, Edinburgh, Scotland, United Kingdom.

Sandra Lauck (S)

Centre for Heart Valve Innovation, St. Paul's Hospital, Vancouver, British Columbia, Canada.

John G Webb (JG)

Centre for Heart Valve Innovation, St. Paul's Hospital, Vancouver, British Columbia, Canada.

Geoffrey W Payne (GW)

University of Northern British Columbia, Prince George, British Columbia, Canada.

Philippe Pibarot (P)

Pulmonary and Cardiology Research University Institute, Laval University, Quebec City, Quebec, Canada.

Philipp Blanke (P)

Department of Radiology, St. Paul's Hospital and University of British Columbia, Vancouver, British Columbia, Canada.

Michael A Seidman (MA)

Centre for Heart Lung Innovation, St. Paul's Hospital and University of British Columbia, Vancouver, British Columbia, Canada; Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, British Columbia, Canada.

Jonathon A Leipsic (JA)

Department of Radiology, St. Paul's Hospital and University of British Columbia, Vancouver, British Columbia, Canada; Centre for Heart Lung Innovation, St. Paul's Hospital and University of British Columbia, Vancouver, British Columbia, Canada; Centre for Heart Valve Innovation, St. Paul's Hospital, Vancouver, British Columbia, Canada. Electronic address: jleipsic@providencehealth.bc.ca.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH